“Ranbaxy must comply with the consent decree’s provisions before the FDA can make a determination of whether to allow Toansa to resume supplying products for the US market,” the US FDA said.
Earlier this year, drug inspectors from both the US FDA as well as European Union (EU) had inspected the active pharmaceutical (API) manufacturing facility of Ranbaxy and found significant deviations from the good manufacturing practices prescribed by the regulators. Following that, US FDA was the first to take action against the company in January itself as it stopped supplies of any product manufactured in Toansa to the American market.
However, now EMA says their latest assessment shows the deficiencies in Ranbaxy’s Toansa factory pose no risk to public health. The assessment stands in stark contrast to the response of US regulators to the deficiencies found at the plant, even as both the regulators maintain they are collaborating and sharing information related to Ranbaxy’s Toansa factory to ensure safe medicines in the market.
“The EMA and FDA inspected the Toansa facility using similar quality standards and underlying principles of current good manufacturing practices. Both regulators identified significant manufacturing and other violations that needed to be addressed, and both placed restrictions on the Toansa facility, consistent with each agency’s legal authorities,” US FDA said.